Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canntab Therapeutics Ltd CTABF

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient’s mouth, with an onset of action between five and thirty minutes.


GREY:CTABF - Post by User

Canntab Therapeutics Ltd > What has happened with this PILL ?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Comment by Tonydeon Jun 07, 2018 8:33pm
78 Views
Post# 28142927

RE:RE:RE:RE:What has happened with this PILL ?

RE:RE:RE:RE:What has happened with this PILL ?
JRSDIRECT, please allow me to ask you, where did this "One (1) Year" (you have been mentioning in your last couple of posts) came from?? I believe, (just my opinion) that by the end of the third (3) quarter of this year, Canntab's XR, extended release tablet will be approved and released to the public. Keep in mind that Canntab is working together with Emblem (which they - Emblem- has the sole rights in Canada) on research and development of the 12 to 18 hour duration tablet, from a single dose. The more important joint venture ( partnership) is with Australia's Medical Cannabis Limited (VitaCann), a subsidiary of Queensland Bauxite Limited which ( I believe Jeff Renwick CEO of Canntab said) "represents a strong move into the Australian and Asian markets". As it seems that the Australian government has started to fast - track developing new policies related to cannabis. So, again in my opinion, working with these two entities will definitely shorten the time line.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities